A Phase 4 interventional study of L-arginine aspartate (Targifor) and Placebo L-arginine aspartate (Targifor) in Muscular Fatigue, sponsored by Sanofi. Terminated at 1 site in Brazil. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-16.
Sponsored by Sanofi · Phase 4, Interventional, and Supportive care
The primary purpose of this study is to evaluate the effect of oral administration of L-arginine in the muscular fatigue of the quadriceps, expressed in terms of the Fatigue Resistance Factor (FRF). The secondary purpose of this study is to evaluate the effect of oral administration of L-arginine in the muscular force the quadriceps.
1,860 studies on the registry are indexed under Fatigue; 376 are open to participants now.
This study's enrollment of 36 is below the median of 54 across 1,440 interventional studies indexed under Fatigue.
Browse Fatigue studies →Sanofi is the lead sponsor of 1,508 studies on the registry; 90 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 118 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Healthy young adults for both sex; Age between 20 and 55 years; Slight or moderate physical activity, 30 minutes per day, at least 3 times a week;
Exclusion criteria:
Cardiac or pulmonary disease; Previous history of knee surgery or skeletal muscular dysfunctions in hip, knee or ankle joints; Athletic person (intensive anaerobic activity); None practiced of physical activity regularly; Medications usage
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
L-arginine aspartate (Targifor)
Drug: L-arginine aspartate (Targifor)
Placebo
Drug: Placebo L-arginine aspartate (Targifor)
3g of L-arginine taken orally in a single daily dose for 8 weeks
Placebo of L-arginine taken orally in a single daily dose for 8 weeks
Fatigue Resistance Factor (FRF)
Time frame: Throughout the study
Maximum force in Newton (N) and fast or explosive force
Time frame: at time 30% of the maximum isometric force
Maximum force in Newton (N) and fast or explosive force
Time frame: at time 50% of the maximum isometric force
Maximum force in Newton (N) and fast or explosive force
Time frame: at time 90% of the maximum isometric force
This study is terminated, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi